Objective: To examine exercise as a therapy for people with osteoporos
is. Options: Immobilization, standing low-load and high-load physical
activities. Outcomes: Risk of injury, quality of life, risk of falls a
nd fractures, strength and posture and pain management. Evidence: Rele
vant epidemiologic studies, clinical trials and reviews were examined,
including the large-scale FICSIT trial in the United States, a prospe
ctive 4-year study of women enrolled in an exercise program in Toronto
and the large-scale Study of Osteoporotic Fractures. Values: Minimizi
ng risk of injury and increasing quality of life were given a high val
ue. Benefits, harms and costs: Moderate physical activity in people wi
th osteoporosis can reduce the risk of falls and fractures, decrease p
ain and improve fitness and overall quality of life. IT may also stimu
late bone gain and decrease bone loss. Its positive effects are an adj
unct to other interventions, such as hormonal therapy. It may give pat
ients the confidence to resume regular activity and can provide social
interaction and support. During exercise programs, proper nutrition i
s necessary to prevent excessive weight loss and impaired immune funct
ion resulting from inadequate protein, vitamin and mineral intake. Rec
ommendations: Immobilization should be avoided if possible in anyone w
ith osteoporosis or at increased risk for osteoporosis. Regular, moder
ate physical activity is recommended for those with osteoporosis. Elde
rly people should be assessed for risk of falling to identify those in
greatest need of an exercise program. Community group exercise progra
ms are beneficial. Younger people with osteoporosis also need exercise
that will preserve or improve bone mass, muscular strength, endurance
and cardiovascular fitness. Weight loss as a result of physical activ
ity should be avoided and adequate intake of protein, vitamins and min
erals assured. Because the benefits of physical activity are independe
nt of the effects of other therapies, physical activity is an essentia
l adjunct to appropriate nutrition and other therapies. Validation: Th
ese recommendations were developed by the Scientific Advisory Board of
the Osteoporosis Society of Canada at its 1995 Consensus Conference.
They are in agreement with the position taken on osteoporosis and exer
cise by the United States Centers for Disease control and Prevention a
nd the American College of Sports Medicine. Sponsors: Sponsors of the
1995 conference included the Dairy Farmers of Canada, Eli Lilly Canada
, Inc., Hoffmann-La Roche Canada Ltd., Merck Frosst Canada Inc. and Pr
octor & Gamble Pharmaceuticals Canada Inc.